Please wait
Labcorp Holdings Inc. (LH) is listed on NYQ in the Healthcare sector, with exposure to Diagnostics & Research. This page brings together the current share price, valuation, dividend context, business summary, and a practical current view so you can assess the stock faster.
Healthcare
₦35.7T
1.0%
25.73
Current price
₦436,530.00
Updated Updated 1d ago
Conviction
71/100
Confidence
Low
Market tone
neutral · 71/100
Entry
Medium · 71/100
Recent price action for LH, so the page starts with the stock itself before the deeper analysis.
At least one liquidity signal is strong now, though large orders should still be staged.
Valuation view
Looks relatively cheap vs peers
Income view
Low income profile
Market tone
neutral (71/100) — price action, attention, and recent context all lean here.
Entry view
Medium (71/100) — The company is profitable on the latest reported numbers.
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
Investors usually follow LH for its dividend profile, valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.
Official filings
0
Financial reports and company disclosures captured by Eye.
Market events
0
Insider, filing, dividend, and price events.
Source records
2
Captured updates we can trace.
Whisone is bullish because fundamentals are solid at 71/100 while there is no strong bear warning from the current data. Whisone has moderate conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
ROE
11.0%
Return on equity
ROA
5.3%
Return on assets
Debt / equity
0.83
Lower is usually safer.
P/B ratio
2.74
Useful for book value support.
Dividend yield
1.0%
Current income signal.
85/100
Direction
Positive bias
Main supports
Business quality and balance-sheet strength are supporting the outlook.
Recent price behavior and momentum still support follow-through.
Recent price and fundamentals refreshes improve signal reliability.
What can go wrong
Execution risk and market swings can still delay the forecast playing out.
Fair value
₦452,100.00
Analyst view
Buy
Analyst target
₦468,529.41
Forecast refresh
Updated 1d ago
Quality score
70
Growth score
50
These are the external analyst numbers and business outlook figures already synced into the company record.
No external analyst outlook is available for this company yet.
₦1,080.00
2024-11-26
Payment: TBA | Qualification: 2024-11-26 | Yield at declaration: N/A
₦1,080.00
2024-08-29
Payment: TBA | Qualification: 2024-08-29 | Yield at declaration: N/A
Price points saved
252
Latest market date
2026-07-23
LH
Labcorp Holdings Inc.
Price: ₦436,530.00
P/E: 25.725243
Yield: 1.0%
ABBV
AbbVie Inc.
Price: ₦389,040.00
P/E: 127.76354
Yield: 2.7%
ABT
Abbott Laboratories
Price: ₦154,590.00
P/E: 33.352753
Yield: 2.5%
ALGN
Align Technology, Inc.
Price: ₦250,522.50
P/E: 28.248322
Yield: 0.0%
Industry
Diagnostics & Research
Employees
71000
Exchange
NYQ
Ticker
LH
